Research programme: selective androgen receptor modulators - Ligand Pharmaceuticals
Alternative Names: LG 123129; LG 123303; LGD-3129; LGD-3303Latest Information Update: 28 May 2019
Price :
$50 *
At a glance
- Originator Ligand Pharmaceuticals
- Developer Ligand Pharmaceuticals; Viking Therapeutics
- Class Quinolones
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cachexia; Female sexual dysfunction; Hypogonadism; Male sexual dysfunction; Osteoporosis
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Cachexia in USA (PO)
- 28 May 2019 No recent reports of development identified for preclinical development in Female-sexual-dysfunction in USA (PO)
- 28 May 2019 No recent reports of development identified for preclinical development in Male-sexual-dysfunction in USA (PO)